What is Flare Therapeutics?
Based in Cambridge, MA, Flare Therapeutics is pioneering a new therapeutic space by deciphering the biology of transcription factors to create innovative small molecule medicines. Leveraging insights from its scientific founders, the company has identified key druggable 'switch sites' crucial for regulating transcription factors. These targets are essential for addressing mutations that drive disease. Founded in 2021, Flare Therapeutics is positioned to address critical unmet needs in the biotechnology sector through its unique scientific approach.
How much funding has Flare Therapeutics raised?
Flare Therapeutics has raised a total of $290M across 3 funding rounds:
Series A
$82M
Series B
$123M
Series C
$85M
Series A (2021): $82M with participation from Eventide Asset Management, Invus Financial Advisors, Casdin Capital, Nextech Invest, Boxer Capital, and Third Rock Ventures
Series B (2023): $123M led by Eventide Asset Management, Casdin Capital, Pfizer Ventures, Pavilion Capital, Boxer Capital, GordonMD Global Investments, and ShangBay Capital
Series C (2026): $85M supported by Boxer Capital, GordonMD Global Investments, Nextech Invest, Third Rock Ventures, Casdin Capital, Lilly, Novartis, Agent Capital, Eventide Asset Management, and Pfizer
Key Investors in Flare Therapeutics
Eventide Asset Management
Eventide Asset Management is an investment firm that focuses on integrity, impact, and outperformance, offering a range of mutual funds and emphasizing a values-based approach to investing in various sectors, including healthcare.
Casdin Capital
Casdin Capital is a venture capital firm with deep expertise in financing life science innovation, particularly in diagnostics and molecular information, and has a history of investing in pioneering companies in the biotech space.
Boxer Capital
Boxer Capital is a private investment fund concentrating on biotechnology drug development across multiple therapeutic indications, managing a portfolio of both public and private companies.
What's next for Flare Therapeutics?
The recent major strategic investment signals a pivotal growth phase for Flare Therapeutics, likely enabling the company to accelerate its research and development pipeline, expand its clinical trial capabilities, and further solidify its market position. This infusion of capital is expected to support the advancement of its novel therapeutic candidates targeting transcription factor dysregulation, potentially leading to breakthroughs in treating a range of diseases. The company's trajectory suggests a focus on scaling operations and advancing its platform towards commercialization.
See full Flare Therapeutics company page
